In the last three months, 8 analysts have published ratings on Healthpeak Properties (NYSE:DOC), offering a diverse range of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 1 | 5 | 2 | 0 | 0 |
Last 30D | 1 | 0 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 1 | 0 | 0 |
2M Ago | 0 | 3 | 1 | 0 | 0 |
3M Ago | 0 | 2 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $24.75, a high estimate of $28.00, and a low estimate of $22.00. Observing a 11.24% increase, the current average has risen from the previous average price target of $22.25.
A clear picture of Healthpeak Properties's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Omotayo Okusanya | Deutsche Bank | Raises | Buy | $28.00 | $20.00 |
Connor Siversky | Wells Fargo | Raises | Equal-Weight | $23.00 | $22.00 |
James Kammert | Evercore ISI Group | Raises | Outperform | $26.00 | $25.00 |
Nicholas Yulico | Scotiabank | Raises | Sector Outperform | $24.00 | $23.00 |
James Kammert | Evercore ISI Group | Raises | Outperform | $25.00 | $24.00 |
Michael Bilerman | Citigroup | Raises | Neutral | $22.00 | $20.00 |
Michael Carroll | RBC Capital | Raises | Outperform | $25.00 | $22.00 |
Richard Anderson | Wedbush | Raises | Outperform | $25.00 | $22.00 |
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Healthpeak Properties's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Healthpeak Properties analyst ratings.
Healthpeak owns a diversified healthcare portfolio of approximately 748 in-place properties spread across mainly medical office and life science assets, plus a handful of senior housing, hospital, and skilled nursing/post-acute care assets, as well.
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3 months period, Healthpeak Properties showcased positive performance, achieving a revenue growth rate of 27.31% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Real Estate sector.
Net Margin: Healthpeak Properties's net margin excels beyond industry benchmarks, reaching 21.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Healthpeak Properties's ROE stands out, surpassing industry averages. With an impressive ROE of 1.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Healthpeak Properties's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.72%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.02.
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.